Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease

Pathophysiology

Volumn 19, Issue 2, 2012, Pages 115-119

  Hashemi, Mohammad ^a,b   Bahari, Ali ^c   Hashemzehi, Norallah ^a   Moazeni Roodi, Abdolkarim ^d   Shafieipour, Sara ^e   Bakhshipour, Alireza ^a   Ghavami, Saeid ^f  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Aryl esterase; Iranians; NAFLD; Nonalcoholic fatty liver disease; Paroxonase; Sera

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE COMPLEX; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84861920266     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2012.04.001     Document Type: Article

References (37)

1. Hashemi M., Bahari A., Bahari G., Ghavami S. Coenzyme Q10 may be effective in the treatment of non alcoholic fatty liver disease (NAFLD). Iranian Journal of Medical Hypotheses and Ideas 2008, 2.
2. Day C.P., James O.F. Steatohepatitis: a tale of two " hits" ?. Gastroenterology 1998, 114:842-845.
3. Chitturi S., Farrell G.C. Etiopathogenesis of nonalcoholic steatohepatitis. Seminars in Liver Disease 2001, 21:27-41.
4. Diehl A.M. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. American Journal of Physiology Gastrointestinal and Liver Physiology 2002, 282:G1-G5.
5. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. Journal of Clinical Investigation 2000, 105:1067-1075.
6. George J., Pera N., Phung N., Leclercq I., Yun Hou J., Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology 2003, 39:756-764.
7. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. Journal of Hepatology 2006, 45:51-59.
8. Kedage V., Muttigi M.S., Shetty M.S., Suvarna R., Rao S.S., Joshi C., et al. Serum paraoxonase 1 activity status in patients with liver disorders. Saudi Journal of Gastroenterology 2010, 16:79-83.
9. La Du B.N. Structural and functional diversity of paraoxonases. Nature Medicine 1996, 2:1186-1187.
10. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
11. Aviram M., Rosenblat M. Paraoxonases 1,2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radical Biology and Medicine 2004, 37:1304-1316.
12. Ferre N., Camps J., Prats E., Vilella E., Paul A., Figuera L., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry 2002, 48:261-268.
13. Marsillach J., Ferre N., Vila M.C., Lligona A., Mackness B., Mackness M., et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clinical Biochemistry 2007, 40:645-650.
14. Prakash M., Shetty J.K., Tripathy S., Verma M., Vasudev S., Bhandary P.V. Serum paraoxonase in alcohol abusers associated with alcoholic liver disease. Clinica Chimica Acta 2007, 378:232-234.
15. Kilic S.S., Aydin S., Kilic N., Erman F., Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World Journal of Gastroenterology 2005, 11:7351-7354.
16. M. Hashemi, H. Hosseini, P. Yaghmaei, A. Moazeni-Roodi, A. Bahari, N. Hashemzehi, et al., Association of polymorphisms in glutamate-cysteine ligase catalytic subunit (GCLC) and microsomal triglyceride transfer protein (MTTP) genes with nonalcoholic fatty liver disease, DNA and Cell Biology 30 (2011) 469-575.
17. Kordi-Tamandani D.M., Hashemi M., Birjandian E., Bahari A., Valizadeh J., Torkamanzehi A. Lack of association of GSTT1 and GSTP1 genes methylation and their expression profiles with risk of NAFLD in a sample of Iranian patients. Clinics and Research in Hepatology and Gastroenterology 2011, 35:387-392.
18. Hashemi M., Kordi-Tamandani D.M., Sharifi N., Moazeni-Roodi A., Kaykhaei M.A., Narouie B., et al. Paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, Southeast Iran. European Journal of Endocrinology 2011, 164:219-222.
19. Naderi M., Hashemi M., Komijani-Bozchaloei F., Moazeni-Roodi A., Momenimoghaddam M. Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis. Pathophysiology 2011, 18:117-120.
20. Sanyal A.J. Review article: non-alcoholic fatty liver disease and hepatitis C-risk factors and clinical implications. Alimentary Pharmacology and Therapeutics 2005, 22(Suppl. 2):48-51.
21. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
22. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 2004, 114:147-152.
23. Hashemi M., Moazeni-Roodi A.K., Fazaeli A., Sandoughi M., Taheri M., Bardestani G.R., et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genetics and Molecular Research 2010, 9:1735-1741.
24. Hashemi M., Moazeni-Roodi A.K., Fazaeli A., Sandoughi M., Bardestani G.R., Kordi-Tamandani D.M., et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genetics and Molecular Research 2010, 9:333-339.
25. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:516-521.
26. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
27. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation 1997, 99:62-66.
28. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993, 3:73-76.
29. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., et al. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
30. Aslan M., Horoz M., Nazligul Y., Bolukbas C., Bolukbas F.F., Selek S., et al. Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis. International Journal of Clinical Practice 2008, 62:1050-1055.
31. Baskol G., Baskol M., Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clinical Biochemistry 2007, 40:776-780.
32. Brunt E.M. Nonalcoholic steatohepatitis. Seminars in Liver Disease 2004, 24:3-20.
33. Ferre N., Camps J., Cabre M., Paul A., Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism: Clinical and Experimental 2001, 50:997-1000.
34. Ferre N., Marsillach J., Camps J., Rull A., Coll B., Tous M., et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clinica Chimica Acta 2005, 361:206-210.
35. Marsillach J., Bertran N., Camps J., Ferre N., Riu F., Tous M., et al. The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clinical Biochemistry 2005, 38:1138-1140.
36. Marsillach J., Camps J., Ferre N., Beltran R., Rull A., Mackness B., et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 2009, 9:3.
37. Marsillach J., Aragones G., Mackness B., Mackness M., Rull A., Beltran-Debon R., et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids in Health and Disease 2010, 9:46.